Canada markets closed

Virios Therapeutics, Inc. (VIRI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
6.36+0.48 (+8.16%)
At close: 04:00PM EST
6.67 +0.31 (+4.87%)
After hours: 05:06PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close5.88
Open5.99
Bid6.27 x 1000
Ask6.67 x 800
Day's Range5.84 - 6.45
52 Week Range4.00 - 8.79
Volume57,475
Avg. Volume32,355
Market Cap52.981M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.38
Earnings DateAug. 12, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.33
  • Business Wire

    Virios Therapeutics to Present at the Virtual H.C. Wainwright BioConnect Conference

    ATLANTA, January 04, 2022--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that Greg Duncan, Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright BioConnect Conference, which is taking place virtually January 10 - 13, 2022.

  • Business Wire

    Virios Therapeutics Achieves Over 50% Enrollment Milestone in its Phase 2b Clinical Trial for Fibromyalgia

    ATLANTA, December 01, 2021--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that more than 50% of the patients planned for the Phase 2b FORTRESS (Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of HSV-1) study have been randomized.

  • Business Wire

    Virios Therapeutics Announces Third Quarter 2021 Financial Results and Provides Corporate Update

    ATLANTA, November 11, 2021--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, reported today financial results for the third quarter ended September 30, 2021 and provided a corporate update at 8:30 a.m. EST.